Cancer Family
Hepatobiliary Neoplasm
CI-CAN-00000198Explore in graph →
Non-malignant1,187 active trials17 approved drugs42 evidence items
- NCIt
- C8614
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000198Explore in graph →
Clinical trials
5,262 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04507503 | Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements | approved for marketing | — | — | Taiho Oncology, Inc.INDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04100694 | Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor | approved for marketing | — | — | Merus B.V.INDUSTRY | 0 | May 20, 2025 |
| clinicaltrials |
| NCT00906984 | TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma(TheraSphere) | approved for marketing | — | — | University of California, IrvineOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT05345678 | Himalaya Early Access Program | approved for marketing | — | — | AstraZenecaINDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT01076517 | A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma | approved for marketing | — | — | Stanford UniversityOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT02436044 | HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC | approved for marketing | — | — | Ming ZhaoOTHER | 1 | Aug 20, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Mar 10, 2026source: clinicaltrials